Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Buyout

A bidding war for a start-up developing a promising late-stage melanoma drug drives the deal value sky high.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet